A life science professional and entrepreneur with an extensive professional background that includes product development, research, and general administration, Alexander Cherkassky began his two-decade career at Thermo Fisher Scientific as an organic laboratory supervisor. Alexander Cherkassky currently serves as vice president of mass cytometry and spatial tissue imaging franchise, Fluidigm, in California.
On January 24, 2022, the board of the accredited California-based life-science equipment manufacturer Fluidigm Inc. announced the approval of a $250 million capital infusion from Viking Global Investors LP and Casdin Capital LLC. The investors are looking to improve R&D efforts to strengthen and expand the company’s two major platforms – microfluidics and mass cytometry. Casdin and Viking have built solid reputations in the life sciences and biotechnology spheres through strategic capital injections into promising companies in the sectors. Their investment efforts partly center around value creation and an efficient financial structure.
The company expects the investment to close in the first quarter of 2022. The company will likely be renamed Standard BioTools Inc. to reflect its technologies and mission better.
Alexander Cherkassky 